{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Biological Agent[C307]|Recombinant Cytokine[C1283]" in comments (approximate match)
Status:
US Approved Rx
(1993)
Source:
BLA103471
(1993)
Source URL:
First approved in 1993
Source:
BLA103471
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1992)
Source:
BLA103293
(1992)
Source URL:
First approved in 1992
Source:
BLA103293
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1990)
Source:
BLA103836
(1990)
Source URL:
First approved in 1990
Source:
BLA103836
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02923921: Phase 3 Interventional Completed Pancreatic Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01152788: Phase 2 Interventional Completed Melanoma
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:sampeginterferon beta-1a [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00031733: Phase 2 Interventional Completed Intraocular Melanoma
(2002)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00146432: Phase 2/Phase 3 Interventional Completed Septicemia
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Class:
PROTEIN
